30 October
2024
PureTech Health plc
PureTech to Present at Two Upcoming Investor
Conferences
PureTech Health
plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to changing the
lives of patients with devastating diseases, today announced that
members of the management team will participate in two upcoming
investor conferences. Webcasts of the presentations will be
available at https://investors.puretechhealth.com.
UBS Global
Healthcare Conference
Presenters: Bharatt Chowrira,
Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D.,
Co-founder and President
Date: Wednesday, November 13,
2024
Time: 8:45 a.m. PST
Jefferies London
Healthcare Conference
Presenters: Bharatt Chowrira,
Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D.,
Co-founder and President
Date: Tuesday, November 19,
2024
Time: 2:30 p.m. GMT
About PureTech
Health
PureTech is a clinical-stage biotherapeutics company
dedicated to giving life to new classes of medicine to change the
lives of patients with devastating diseases. The Company has
created a broad and deep pipeline through its experienced research
and development team and its extensive network of scientists,
clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D
engine has resulted in the development of 29 therapeutics and
therapeutic candidates, including three that have been approved by
the U.S. Food and Drug Administration. A number of these programs
are being advanced by PureTech or its Founded Entities in various
indications and stages of clinical development, including
registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points.
For more information, visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Cautionary Note
Regarding Forward-Looking Statements
This press release contains statements that are or
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under
the caption "Risk Factors" in our Annual Report on Form 20-F for
the year ended December 31, 2023, filed with the SEC and in our
other regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU
Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US Media
Justin Chen
+1-609-578-7230
jchen@tenbridgecommunications.com